Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1115-1122

  Anderson, Jenna ^a   Hägglund, Sara ^a   Bréard, Emmanuel ^b   Comtet, Loic ^c   Bengtsson, Karin Lövgren ^d   Pringle, John ^a   Zientara, Stéphan ^b   Valarchera, Jean Francois ^a,e  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^c ID VET   (France)

^d ISCONOVA AB   (Sweden)

^e NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLUETONGUE ORBIVIRUS VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; PLACEBO; PROTEIN VP2; PROTEIN VP7; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLUETONGUE; BLUETONGUE ORBIVIRUS; BLUETONGUE ORBIVIRUS 8; CELLULAR IMMUNITY; CONTROLLED STUDY; COW; CROSS REACTION; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; CATTLE; CATTLE DISEASES; T-LYMPHOCYTES; VACCINES, MARKER; VACCINES, SUBUNIT; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84880873669     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00229-13     Document Type: Article

References (57)

1. Purse BV, Mellor PS, Rogers DJ, Samuel AR, Mertens PPC, Baylis M. 2005. Climate change and the recent emergence of bluetongue in Europe. Nat. Rev. Microbiol. 3:171-181.
2. Caporale V, Giovannini A. 2010. Bluetongue control strategy, including recourse to vaccine: a critical review. Rev. Sci Tech. 29:573-591.
3. Roy P, Boyce M, Noad R. 2009. Prospects for improved bluetongue vaccines. Nat. Rev. Microbiol. 7:120-128.
4. Ferrari G, De Liberato C, Scavia G, Lorenzetti R, Zini M, Farina F, Magliano A, Cardeti G, Scholl F, Guidoni M, Scicluna MT, Amaddeo D, Scaramozzino P, Autorino GL. 2005. Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy. Prev. Vet. Med. 68:103-113.
5. Savini G, MacLachlan NJ, Sanchez-Vizcaino Zientara J-MS. 2008. Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 31:101-120.
6. Veronesi E, Hamblin C, Mellor PS. 2005. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23:5509-5516.
7. Stewart M, Bhatia Y, Athmaran TN, Noad R, Gastaldi C, Dubois E, Russo P, Thiéry R, Sailleau C, Bréard E, Zientara S, Roy P. 2010. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. Vaccine 28:3047-3054.
8. Perrin A, Albina E, Bréard E, Sailleau C, Promé S, Grillet C, Kwiatek O, Russo P, Thiéry R, Zientara S, Cêtre-Sossah C. 2007. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25:6774- 6783.
9. Boone JD, Balasuriya UB, Karaca K, Audonnet J-C, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, MacLachlan NJ. 2007. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25:672-678.
10. Wade-Evans AM, Pullen L, Hamblin C, O'Hara R, Burroughs JN, Mertens PP. 1997. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge. J. Gen. Virol. 78:1611-1616.
11. Calvo-Pinilla E, Navasa N, Anguita J, Ortego J. 2012. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7:e34735. doi:10.1371/journal.pone .0034735.
12. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek- Bankowska K, Alpar O, Ortego J, Takamatsu H-H, Mertens PPC, Castillo- Olivares J. 2013. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 8:e60574. doi:10 .1371/journal.pone.0060574.
13. Giovannini A, MacDiarmid S, Calistri P, Conte A, Savini L, Nannini D, Weber S. 2004. The use of risk assessment to decide the control strategy for bluetongue in Italian ruminant populations. Risk Anal. 24:1737-1753.
14. Alpar HO, Bramwell VW, Veronesi E, Darpel KE, Pastoret P-P, Mertens PPC. 2009. Bluetongue virus vaccines past and present, p 397- 428. In Mellor PS, Baylis M, Mertens PPC (ed), Bluetongue. Elsevier, New York, NY.
15. Patta C, Giovannini A, Rolesu S, Nannini D, Savini G, Calistri P, Santucci U, Caporale V. 2004. Bluetongue vaccination in Europe: the Italian experience. Vet. Ital. 40:601-610.
16. Zientara S, Sánchez-Vizcaíno JM. 2013. Control of bluetongue in Europe. Vet. Microbiol. [Epub ahead of print.] doi:10.1016/j.vetmic.2013.01.010.
17. MacLachlan NJ, Osburn BI. 2006. Impact of bluetongue virus infection on the international movement and trade of ruminants. J. Am. Vet. Med. Assoc. 228:1346-1349.
18. Hamers C, Galleau S, Chery R, Blanchet M, Besancon L, Cariou C, Werle-Lapostolle B, Hudelet P, Goutebroze S. 2009. Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle. Vet. Rec. 165:369-373.
19. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ. 1990. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64:1998-2003.
20. Bhanuprakash V, Indrani B, Hosamani M, Balamurugan V, Singh R. 2009. Bluetongue vaccines: the past, present and future. Expert Rev. Vaccines 8:191-204.
21. Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, Nunes SF, Armezzani A, Bayoumy A, Rixon F, Shaw A, Palmarini M. 2011. Identification and characterization of a novel non-structural protein of bluetongue virus. PLoS Pathog. 7:e1002477. doi:10.1371/journal.ppat .1002477.
22. International Committee on Taxonomy of Viruses. 2011. Virus taxonomy: ninth report of the International Committee on Taxonomy of Viruses. Elsevier, Oxford, United Kingdom.
23. Schwartz-Cornil I, Mertens PPC, Contreras V, Hemati B, Pascale F, Bréard E, Mellor PS, MacLachlan NJ, Zientara S. 2008. Bluetongue virus: virology, pathogenesis and immunity. Vet. Res. 39:46.
24. Hassan SS, Roy P. 1999. Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry. J. Virol. 73:9832-9842.
25. Maan S, Maan NS, Nomikou K, Veronesi E, Bachanek-Bankowska K, Belaganahalli MN, Attoui H, Mertens PPC. 2011. Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait. PLoS One 6:e26147. doi:10.1371/journal.pone.0026147.
26. Huismans H, Erasmus BJ. 1981. Identification of the serotype-specific and group-specific antigens of bluetongue virus. Onderstepoort J. Vet. Res. 48:51-58.
27. Mertens PPC, Maan NS, Prasad G, Samuel AR, Shaw AE, Potgieter AC, Anthony SJ, Maan S. 2007. Design of primers and use of RT-PCR assays for typing European bluetongue virus isolates: differentiation of field and vaccine strains. J. Gen. Virol. 88:2811-2823.
28. Kahlon J, Sugiyama K, Roy P. 1983. Molecular basis of bluetongue virus neutralization. J. Virol. 48:627-632.
29. Shaw AE, Ratinier M, Nunes SF, Nomikou K, Caporale M, Golder M, Allan K, Hamers C, Hudelet P, Zientara S, Breard E, Mertens P, Palmarini M. 2013. Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment. J. Virol. 87:543-557.
30. Stewart M, Dovas CI, Chatzinasiou E, Athmaram TN, Papanastassopoulou M, Papadopoulos O, Roy P. 2012. Protective efficacy of bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype- specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 30:2131-2139.
31. Inumaru S, Roy P. 1987. Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector. Virology 157:472-479.
32. Andrew M, Whiteley P, Janardhana V, Lobato Z, Gould A, Coupar B. 1995. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet. Immunol. Immunopathol. 47:311-322.
33. Roy P, Bishop DHL, LeBlois H, Erasmus BJ. 1994. Long-lasting protection of sheep against bluetongue challenge after vaccination with viruslike particles: evidence for homologous and partial heterologous protection. Vaccine 12:805-811.
34. Jones LD, Williams T, Bishop D, Roy P. 1997. Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection. Clin. Diagn. Lab. Immunol. 4:297-301.
35. Stott JL, Barber TL, Osburn BI. 1985. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am. J. Vet. Res. 46:1043-1049.
36. Jones LD, Chuma T, Hails R, Williams T, Roy P. 1996. The nonstructural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants. J. Gen. Virol. 77:997-1003.
37. Anderson J, Mertens PP, Herniman KA. 1993. A competitive ELISA for the detection of anti-tubule antibodies using a monoclonal antibody against bluetongue virus non-structural protein NS1. J. Virol. Methods 43:167-175.
38. Mecham JO, Dean VC, Jochim MM. 1986. Correlation of serotype specificity and protein structure of the five U.S. serotypes of bluetongue virus. J. Gen. Virol. 67:2617-2624.
39. Barros SC, Cruz B, Luís TM, Ramos F, Fagulha T, Duarte M, Henriques M, Fevereiro M. 2009. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus. Vet. Microbiol. 137:252-259.
40. Hamblin C. 2004. Bluetongue virus antigen and antibody detection, and the application of laboratory diagnostic techniques. Vet. Ital. 40:538-545.
41. Vandenbussche F, Vanbinst T, Verheyden B, Van Dessel W, Demeestere L, Houdart P, Bertels G, Praet N, Berkvens D, Mintiens K, Goris N, De Clercq K. 2008. Evaluation of antibody-ELISA and real-time RT-PCR for the diagnosis and profiling of bluetongue virus serotype 8 during the epidemic in Belgium in 2006. Vet. Microbiol. 129:15-27.
42. Taylor G, Thomas LH, Wyld SG, Furze J, Sopp P, Howard CJ. 1995. Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. J. Virol. 69:6658-6664.
43. Bréard E, Belbis G, Hamers C, Moulin V, Lilin T, Moreau F, Millemann Y, Montange C, Sailleau C, Durand B, Desprat A, Viarouge C, Hoffmann B, de Smit H, Goutebroze S, Hudelet P, Zientara S. 2011. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats. Vaccine 29: 2495-2502.
44. R Development Core Team. 2012. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
45. Huismans H, van Der Walt NT, Cloete M, Erasmus BJ. 1987. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology 157:172-179.
46. Eschbaumer M, Hoffmann B, König P, Teifke JP, Gethmann JM, Conraths FJ, Probst C, Mettenleiter TC, Beer M. 2009. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep. Vaccine 27:4169-4175.
47. Bartram DJ, Heasman L, Batten CA, Oura CAL, Plana-Durán J, Yuen HM, Wylie ADM. 2011. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines. Vet. J. 188:193-196.
48. Gethmann J, Hüttner K, Heyne H, Probst C, Ziller M, Beer M, Hoffmann B, Mettenleiter TC, Conraths FJ. 2009. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 27:4118-4126.
49. Wäckerlin R, Eschbaumer M, König P, Hoffmann B, Beer M. 2010. Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle. Vaccine 28:4348-4355.
50. Toussaint JF, Sailleau C, Breard E, Zientara S, De Clercq K. 2007. Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. J. Virol. Methods 140:115-123.
51. Adkison MA, Stott JL, Osburn BI. 1988. Temporal development of bluetongue virus protein-specific antibody in sheep following natural infection. Vet. Microbiol. 16:231-241.
52. Butan C, Tucker P. 2010. Insights into the role of the non-structural protein 2 (NS2) in bluetongue virus morphogenesis. Virus Res. 151:109- 117.
53. Morein B, Bengtsson KL. 1999. Immunomodulation by iscoms, immune stimulating complexes. Methods 19:94-102.
54. Hägglund S, Hu K, Vargmar K, Poré L, Olofson Blodörn A-SK, Anderson J, Ahooghalandari P, Pringle J, Taylor G, Valarcher J-F. 2011. Bovine respiratory syncytial virus ISCOMs: immunity, protection and safety in young conventional calves. Vaccine 29:8719-8730.
55. Janardhana V, Andrew ME, Lobato ZI, Coupar BE. 1999. The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res. Vet. Sci. 67: 213-221.
56. Pérez de Diego AC, Sánchez-Cordón PJ, de las Heras AI, Sánchez- Vizcaíno JM. 2012. Characterization of the immune response induced by a commercially available inactivated bluetongue virus serotype 1 vaccine in sheep. Scientific World Journal 2012:147158. doi:10.1100/2012/147158.
57. Zhou E-M, Ridd D, Riva J, Fernando L, Clavijo A. 2001. Development and evaluation of an IgM-capture ELISA for detection of recent infection with bluetongue viruses in cattle. J. Virol. Methods 91:175-182.